News

Yahoo Finance3d
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 1 1-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear ...
Morningstar3d
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-in-class TRPM8 ...
USA Today19d
Artificial tears, other eye products recalled; consumers urged to discontinue use
Over-the-counter ophthalmic products were voluntarily recalled due to a manufacturing deviation discovered during a U.S. Food and Drug Administration audit, a notice says. Pharmaceutical ...
Morningstar3d
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation.5-7 Many commonly used DED treatment ...
Local 12 WKRC Cincinnati20d
Eye care products sold nationwide recalled, consumers advised to stop use immediately
The affected products include: Artificial Tears Ophthalmic Solution (NDC# 50268-043-15) Carboxymethylcellulose Sodium Ophthalmic Gel 1% (NDC# 50268-066-15) Carboxymethylcellulose Sodium Ophthalmic ...
FOX8 Cleveland17d
Urgent safety recall for eye care products
Artificial Tears Ophthalmic Solution (NDC# 50268-043-15) Carboxymethylcellulose Sodium Ophthalmic Gel 1% (NDC# 50268-066-15) Carboxymethylcellulose Sodium Ophthalmic Solution (NDC# 50268-068-15 ...